Nuo Therapeutics, Inc. filings document a commercial-stage medical-device issuer focused on Aurix, its autologous platelet-rich plasma system for chronic wound management. The company’s regulatory record includes Current Reports on Form 8-K for material events, material agreements, capital-structure disclosures, governance matters, operating and financial results, and security-structure updates.
Proxy and annual-meeting filings describe board elections, auditor ratification, advisory executive-compensation votes, shareholder proposal procedures, and voting results. These disclosures also cover compensation arrangements, board and committee actions, common-stock matters, and public-company governance tied to commercialization of the Aurix System.
Nuo Therapeutics, Inc. director reports stock option exercise. A director of Nuo Therapeutics exercised an option to purchase 50,000 shares of common stock at an exercise price of $0.40 per share through a net exercise on December 9, 2025. The transaction resulted in the director receiving 40,909 shares of common stock, while 9,091 shares underlying the option were withheld to cover the exercise price using a closing market price of $2.20 per share. Following these transactions, the director beneficially owns 108,294 shares of Nuo Therapeutics common stock in direct ownership.
Nuo Therapeutics, Inc. director filed a Form 4 reporting an option exercise and related share withholding. On 12/09/2025, the insider exercised an option to purchase 50,000 shares of common stock at an exercise price of $0.40 per share. As part of a net exercise, the issuer withheld 9,091 shares of common stock at a closing price of $2.20 to cover the exercise cost, and the reporting person received 40,909 shares of common stock. Following these transactions, the insider directly beneficially owned 108,294 shares of Nuo Therapeutics common stock.
Nuo Therapeutics, Inc. reported an insider transaction by CEO/CFO and director David Jorden. On 11/28/2025, he reported a sale of 200,000 shares of common stock at $1.50 per share, leaving him with 1,946,755 shares beneficially owned directly after the trade. The filing notes that the transaction was executed as a private transaction in connection with a personal real estate transaction and that the shares involved are characterized as “restricted” securities under the Securities Act of 1933.
Nuo Therapeutics (AURX) reported Q3 2025 results showing faster top-line growth but ongoing losses and liquidity pressure. Total revenue rose to $1,032,096 from $370,951 a year ago, driven by $957,096 in product sales and $75,000 recognized from the Smith+Nephew distribution fee. Gross profit was $625,375; gross margin was 61% versus 73% last year due to low‑margin centrifuge device sales to Smith+Nephew and tariff surcharges, partly offset by fee revenue with no cost.
Operating expenses were $1,165,517, and net loss was $537,919 (basic/diluted loss per share $0.01). For the nine months, revenue reached $2,216,679 with a net loss of $1,933,736. Cash was $514,797 as of September 30, 2025, with total deferred revenue of $1,350,000 tied to the Smith+Nephew upfront distribution fee. The company raised $791,418 in a July private placement and $113,541 from option exercises. Management states substantial doubt about the ability to continue as a going concern, citing expected cash needs beyond current resources despite the new distribution agreement.
Nuo Therapeutics, Inc. announced its Annual Meeting of Stockholders for December 16, 2025 at 9 a.m. CST at its Houston headquarters. Stockholders of record at the close of business on October 27, 2025 may vote; there were 48,077,745 shares outstanding on the record date.
Three items are up for vote: elect four directors (David E. Jorden, Paul D. Mintz, Scott M. Pittman, and C. Eric Winzer), ratify MaloneBailey LLP as independent auditor for 2025, and an advisory “say‑on‑pay” vote on named executive officer compensation. The Board recommends voting FOR all proposals, with directors elected by plurality and Proposal 2 and 3 by majority of shares present and entitled to vote.
The proxy notes MaloneBailey has served since June 7, 2024; Marcum LLP was dismissed the same day. Marcum’s prior reports included going concern explanatory paragraphs and the company identified material weaknesses tied to limited accounting resources. Director compensation resumed in 2024–2025, and effective October 1, 2025 base salaries increased to $325,000 for the CEO/CFO and $290,000 for the CSOO. Principal holders include Charles E. Sheedy 24.1% and Scott M. Pittman 11.6%.
Nuo Therapeutics, Inc. reported two governance actions: the board approved salary increases for its top executives and set the date for the 2025 Annual Meeting of Stockholders. Effective October 1, 2025, the salary for Chief Executive and Financial Officer David E. Jorden is $325,000 and the salary for Chief Scientific and Operating Officer Peter A. Clausen is $290,000. The board said the Committee considered an improvement in the company’s business and financial condition in 2025 when approving the increases.
The board fixed the Annual Meeting to be held at the company’s principal executive office on December 16, 2025. Stockholder proposals and director nominations for inclusion in the proxy materials must be received by the company’s Secretary by the close of business on October 20, 2025 and must comply with the company’s By-Laws and SEC rules.